Randomized phaze II clinical trial of intermittent docetaxel plus prednisone for the treatment of hormone-refractory prostate cancer
Phase 2
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000002298
- Lead Sponsor
- Kitasato University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. active infection 2. history of previous radiotherapy to pelvis, severe comorbidity, history of any other malignancy which includes synchronal double cancer 3. chest Xray shows obvious interstitial pneumonia and pulmonary fibrosis 4. patients who have been included in another clinical trial less than 6 months before agreement of this trial 5. patients who are judged as unsuitable for the trial by the doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method QOL (before administration of Docetaxel, every 3 weeks when chemotherapy is paused)
- Secondary Outcome Measures
Name Time Method Time to failure, Adverse Events, Overall mortality